Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair®)

Summary

Omalizumab (Xolair^®) is an anti-IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment with omalizumab in two toddlers with severe diffuse cutaneous mastocytosis. Our cases offer preliminary evidence to support the safe use of omalizumab in paediatric patients with cutaneous mastocytosis.

http://ift.tt/2ByfdCT